These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 18604455)
1. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Katsara M; Matsoukas J; Deraos G; Apostolopoulos V Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):636-42. PubMed ID: 18604455 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies. Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991 [TBL] [Abstract][Full Text] [Related]
3. Novel promising therapeutic agents in multiple sclerosis. Mirshafiey A Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):218-4. PubMed ID: 19075984 [TBL] [Abstract][Full Text] [Related]
4. Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients. Rostami Mansoor S; Ghasemi-Kasman M J Med Virol; 2021 Mar; 93(3):1314-1319. PubMed ID: 33044760 [TBL] [Abstract][Full Text] [Related]
5. Translating new insights into treatment optimisation in multiple sclerosis. Fazekas F; Kieseier BC J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857 [No Abstract] [Full Text] [Related]
6. [Current state of research on multiple sclerosis]. Lubina-Dabrowska N; Stepień A; Chalimoniuk M Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821 [TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
13. Editorial: the pitfalls of combination therapy. Vermersch P Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074 [No Abstract] [Full Text] [Related]
14. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects. Vidal-Jordana A; Montalban X Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781 [TBL] [Abstract][Full Text] [Related]
15. A changing treatment landscape for multiple sclerosis: challenges and opportunities. Piehl F J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084 [TBL] [Abstract][Full Text] [Related]
16. Choosing drug therapy for multiple sclerosis. An update. van Oosten BW; Truyen L; Barkhof F; Polman CH Drugs; 1998 Oct; 56(4):555-69. PubMed ID: 9806103 [TBL] [Abstract][Full Text] [Related]
17. Flavonoids, the compounds with anti-inflammatory and immunomodulatory properties, as promising tools in multiple sclerosis (MS) therapy: A systematic review of preclinical evidence. Bayat P; Farshchi M; Yousefian M; Mahmoudi M; Yazdian-Robati R Int Immunopharmacol; 2021 Jun; 95():107562. PubMed ID: 33770729 [TBL] [Abstract][Full Text] [Related]